combination therapy – Page 7 – Communicable Diseases Research

Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19

Article

Published on 2022-02-082022-10-28
Journal: Viruses [Category] COVID-19, COVID19(2023년), Fulltext, SARS,

[키워드] acute respiratory syndrome agent Alpha angeloylgomisin O antiviral assay B.1.1.7 B.1.351 caused Cell cellular Combination combination therapy Concentration coronavirus coronavirus disease COVID-19 disease drug drug combination drug library Effect effective Entry inhibitor Health identify impacted infections inhibit inhibit SARS-CoV-2 inhibited lack membrane fusion novel pandemic performed potential therapeutic agent Prevent pseudotype virus Remdesivir S glycoprotein SARS-CoV-2 SARS-CoV-2 entry SARS-CoV-2 S schisandrin B Screening selective specific treatment synergistic the SARS-CoV-2 treat variants
[DOI] 10.3390/v14020353 PMC 바로가기 [Article Type] Article

Brilacidin, a COVID‐19 drug candidate, demonstrates broad‐spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell

Research Article

Published on 2022-02-022022-10-04
Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료제,

Levocetirizine and montelukast in the COVID-19 treatment paradigm

Research article

Published on 2022-02-012022-10-05
Journal: International immunopharmacology [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료법,

[키워드] addition addressed adhesion molecules Anti-inflammatory anti-inflammatory activity approved average Boston Cell cellular clinical Clinical trial design Cohort combination therapy Comorbidity COVID-19 COVID-19 case COVID-19 test deaths FDA Follow-up intubations Laboratory leukocytes leukotriene receptor antagonist levocetirizine Long COVID Massachusett Massachusetts Metrics Mild moderate Montelukast morbidity and mortality mortality rate multicenter outcomes Patient peaked Phase 2 pilot study placebo-controlled positioned Prevent progression Protein Proteins protocol question Randomized reducing second wave Signaling single-center symptoms of COVID-19 synergistic the disease therapeutic treat treated Treatment
[DOI] 10.1016/j.intimp.2021.108412 [Article Type] Research article

Binding of raloxifene to human complement fragment 5a ( h C5a): a perspective on cytokine storm and COVID19

Article

Published on 2022-02-012022-10-04
Journal: Journal of biomolecular structure & dynamics [Category] COVID19(2023년), SARS, 신약개발,

Efficacy of lopinavir–ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis

Meta-Analysis

Published on 2022-01-312022-10-31
Journal: Future Virology [Category] COVID-19,

Dealing with Corticosteroid and High-Dose Cyclosporine Therapy in a Pyoderma Gangrenosum Patient Contracting a COVID-19 Infection

Case Report

Published on 2022-01-272022-10-30
Journal: Journal of Personalized Medicine [Category] COVID-19,

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Review

Published on 2022-01-212023-08-30
Journal: Molecular Cancer [Category] E형 간염,

[키워드] Angiogenesis inhibitor bispecific antibody combination therapy gut microbiota PD-1 PD-L1 Radiotherapy STING
[DOI] 10.1186/s12943-021-01489-2 PMC 바로가기 [Article Type] Review

The Conserved Macrodomain Is a Potential Therapeutic Target for Coronaviruses and Alphaviruses

Perspective

Published on 2022-01-142022-10-28
Journal: Pathogens [Category] COVID-19,

[키워드] acting addition ADP-ribosylation ADP-ribosylhydrolase alphavirus Antiviral Antiviral agents antiviral target antivirals approaches binding pocket combating Combination combination therapy complement conserved Coronaviral coronavirus Coronaviruses COVID-19 COVID-19 pandemic Critical demonstrated develop drug target effective Host inhibitor interferon interferon response lack macrodomain Mutation offer pandemic Pathogenesis Potential protease Protective public health Replication responses RNA polymerase SARS-CoV-2 suppresse target targets Therapeutics Threats Treatment Vaccines viral disease Viral macrodomain virus virus replication
[DOI] 10.3390/pathogens11010094 PMC 바로가기 [Article Type] Perspective

Oral Therapy Using a Combination of Nanotized Antimalarials and Immunomodulatory Molecules Reduces Inflammation and Prevents Parasite Induced Pathology in the Brain and Spleen of P. berghei ANKA Infected C57BL/6 Mice

나노화된 항말라리아제와 면역조절 분자의 조합을 이용한 경구 요법은 P. berghei ANKA에 감염된 C57BL/6 마우스의 뇌와 비장에서 염증을 줄이고 기생충 유도 병리를 예방한다.

Original Research

Published on 2022-01-132024-08-08
Journal: Frontiers in immunology [Category] 말라리아,

[키워드] combination therapy experimental cerebral malaria (ECM) inflammation control P. berghei ANKA recrudescence
[DOI] 10.3389/fimmu.2021.819469 PMC 바로가기 [Article Type] Original Research

Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties

Research Article

Published on 2022-01-112022-10-30
Journal: JCI Insight [Category] COVID-19,